scm logo

Appointment of CEO Yoo-Jeong Kim

Registration of patent for Cosmetic composition containing stem cell conditioned medium and Centella asiatica exosomes

Registration of patent for Cosmetic composition containing stem cell conditioned medium, Centella asiatica leaf water, and peptides

Registration of Australian patent for Composition for enhancing stem cell functionality

Appointment of CEO Ki-Ryung Song

Registration of Chinese patent for Pharmaceutical composition for treating atopic dermatitis comprising clonal stem cells

Registration of patent for Composition for prevention or treatment of atopic dermatitis containing functionally enhanced stem cells

Registration of patent for Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising clonal stem cells

Registration of European patent for Pharmaceutical composition comprising clonal stem cells for the treatment of pancreatitis and graft-versus-host disease (GVHD)

Publication of Phase 1/2 clinical study results for moderate-to-severe atopic dermatitis in the Journal of Allergy and Clinical Immunology

Registration of Japanese patent for Pharmaceutical composition for treating atopic dermatitis comprising clonal stem cells

Exclusive distribution agreement with Cherry Trading for Iroro products in Vietnam

Exclusive distribution agreement with Regina Skin Medical for Iroro products in Hong Kong

Registration of Singapore patent for Pharmaceutical composition for prevention or treatment of Treg-mediated immune diseases

Registration of Japanese patent for Composition for enhancing stem cell functionality

Publication in Cell Death & Disease (December 2023 issue) – study on Ahr-mediated immunomodulatory mechanism of mesenchymal stem cells

Exclusive licensing agreement with Isblanc Co., Ltd. for Iroro Newborn Skincare products in Japan

Registration of patent for Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising clonal stem cells

Registration of Indonesian patent for Method for layered culturing and proliferation of stem cells

Publication of Phase 1/2a clinical study results for moderate-to-severe acute pancreatitis in Gastroenterology (June 2023 issue)

Registration of Japanese patent for Cosmetic composition comprising culture medium of mesenchymal stem cells cultured in hPL-containing media

Registration of Japanese trademark “Iroro Nuvon”

Registration of trademarks “Iroro Nutreatment”

Registration of trademarks “Iroro Nutreatment (word mark)”

Registration of Chinese patent for Method for layered culturing and proliferation of stem cells

Registration of patent for Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising clonal stem cells

Registration of patent for Stem cell priming composition and primed stem cells thereof

Registration of Japanese patent for Pharmaceutical composition comprising inflammation-stimulated mesenchymal stem cells for prevention or treatment of immune or inflammatory diseases

Korea Digestive Disease Week (KDDW2022) Acute Pancreatitis Stem Cell Treatment Clinical Results Presentation and Best Abstract Award

SCM LifeScience Inc. - Joint Research Team, University of Utah Published a paper in the International Journal of Tissue Engineering using stem cells, a source technology.

SCM Lifescience Inc. - University of Utah Joint Research Team Awarded NIMS Award 2022

Signed a joint business agreement with Inha University, Inha University Hospital, and SCM Lifescience Inc. to promote strategic technology commercialization

Signed a hair care product supply contract with Malaysian pharmaceutical company Duoharma

Completed phase 2a clinical trial for moderate-severe acute pancreatitis stem cell therapy

Inauguration of Son Byong-kwan as the 4th CEO of SCM Lifescience Inc.

Initiation of phase 2 clinical trial for stem cell treatment for atopic dermatitis

Initiation of phase 2a clinical trial for stem cell therapy for moderate to severe acute pancreatitis

US patent registration for pharmaceutical composition for the prevention or treatment of regulatory T cell-mediated diseases

Signed a contract to introduce a license for diabetes treatment with Allial Biotechnology & Pharmaceuticals in the USA

Registered a domestic patent for a composition for enhancing the function of stem cells

Equity investment in Vita Therapeutics, USA

Registered a domestic patent for a pharmaceutical composition for the treatment of graft-versus-host disease containing clonal stem cells

Chinese patent registration of stem cell-derived hair loss prevention composition

Registered a domestic patent for a pharmaceutical composition for the treatment of pancreatitis containing clonal stem cells

Application for approval (IND) for domestic phase 2 clinical trial for the treatment of polyQ spinocerebellar ataxia

Acquired high-tech biopharmaceutical manufacturing license

SCM Lifescience and CHA Biotech signed a contract for the consignment production (CMO) of bone marrow-derived cell therapy products

Selected as a 'Global IP (Intellectual Property) Star Enterprise Promotion Project'

Australian patent registration for pharmaceutical composition for the prevention or treatment of regulatory T cell-mediated diseases

Japanese patent registration for next-generation stem cell isolation and culture method

Official invitation to JPMorgan Healthcare Conference.

Approval of orphan drug designation in domestic development stage for acute pancreatitis treatment (SCM-AGH)

A contract to introduce a domestic exclusive license for stem cell therapy for spinal cerebrosclerosis was signed.

The Ministry of Food and Drug Safety designates a rare drug for acute pancreatitis treatment.

Taiwan’s Steminent Biotherapeutics signs a contract to introduce an exclusive domestic license for Stemchymal, a stem cell treatment for spinal cerebellar ataxia

Completed phase 1 clinical trial for atopic dermatitis treatment

SCM Lifescience and Pharmimex JSC, stem cell technology license out MOU

SCM Lifescience-TheraImmune, start developing cell therapy for autoimmune diseases

SCM Lifescience-PBS Biotech mass-produced stem cell therapy

Listed on KOSDAQ

Acquired and merged with Coimune, an American corporation, and Formulaa, Italy

SCM Lifescience and Inha University Hospital sign a business agreement to develop a treatment for COVID-19

Co-Immune, a U.S. corporation, approved by the U.S. FDA for a phase 2b clinical trial plan for a dendritic cell treatment vaccine for metastatic renal cancer

Awarded the Ministry of Science, Technology and Information and Communication Award for Contribution to Research Industry

Signed MOU with SCM Lifescience and Mitoimmune Therapeutics to develop new drugs for rare diseases

Announcement of designation of SCM-CGH (injection) as 'orphan drug in development stage' (Ministry of Food and Drug Safety Announcement No. 2019 - 278)

SCM Lifescience-Handok equity investment and signing a license out contract for stem cell treatment for severe atopic dermatitis

Signed MOU with SCM Lifescience and T&R Biofab for joint development of 3D bioprinting graft treatment

SCM Lifescience and Ilya Biologics signed an MOU for joint development of high-purity mesenchymal stem cell-derived exosomes

Signed MOU for joint research on next-generation cell therapy products and biomarkers with SCM Lifescience and Syntekabio

KFDA Approval for Extended Clinical Trial for Long-Term Safety Follow-up of SCM-AGH in Patients with Severe Acute Pancreatitis

Awarded the Minister of Food and Drug Safety Award at the 2019 Annual General Meeting of the Korea Biopharmaceutical Association

Foreign investment attraction, CCM Duopharma

SCM Lifescience and University of Utah joint research agreement for stem cell therapy using cell sheet

Attracting 3rd investment from investment institutions

Signed MOU with SCM Lifescience and Toolgen to develop gene-inserted stem cell therapy

Received the Minister of Health and Welfare Award for Meritorious Person in the Health Industry, Song Soon-wook, Executive Vice President

BG Rhee inaugurated as new CEO

Approval of phase 1,2a clinical trial for acute pancreatitis 'SCM-AGH'

Acquired a patent for next-generation stem cell manufacturing technology specializing in immune diseases

Approval of phase 2 clinical trial for acute graft-versus-host disease 'SCM-AGH'

High-purity stem cell isolation and culture method certified as a new health technology (NET)

Identification of the mechanism of action for the treatment of immune diseases through mesenchymal mesenchymal cells (MSCs, adult stem cells) for the first time in the world

Acquired ISO 9001:2015 certification

Signed MOU contract with SCM Lifescience for joint development of MDimmune atopic treatment

Approval of the graft-versus-host disease clinical trial (Phase 2)

Attracting secondary investment from investment institutions

Presentation of a paper on manufacturing high-purity stem cell therapeutics

US MESA invited lecture

Attracting the first investment from investment institutions

Japanese patent registration for graft-versus-host disease treatment technology

Establishment of research institute affiliated with SCM Lifescience Co., Ltd.

Registered US patent for manufacturing method of high-purity stem cell therapy

European Union patent registration for high-purity stem cell isolation technology

Sun U. Song inaugurated as CEO

Established SCM Lifescience Co., Ltd.

Patent registration for high-purity adult stem cell isolation technology in China

Registered Japanese patent for high-purity adult stem cell isolation technology

Patent application for manufacturing method of high-purity stem cell therapy

Graft-versus-host disease clinical trial (Phase 1) completed

Patent application for treatment of acute pancreatitis using high-purity mesenchymal stem cells

Patent application for spinal cord injury treatment using high-purity mesenchymal stem cells

Started graft-versus-host disease clinical trial (Phase 1)

Acquired US patent for high-purity adult stem cell isolation technology

Registered a Korean patent for high-purity adult stem cell isolation technology